Abstract
Gout is the most common type of arthritis and is evoked by arousal of the inflammasome in the presence of urate crystals superponed on a dysmetabolism with urate accumulation. Gout can be cured in most patients but still treatment is suboptimal in the majority of patients. Quality guidelines for management from experts such as from American College of Rheumatology aim to give guidance to US physicians and their own rheumatologists but have a value worldwide. We should know about the updates that were recently made publicly, with their strong and conditional recommendations, as we may learn and improve from their updated guideline.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
De Meulemeester M, Jansen TL, Petersen G, Perez-Ruiz F (2019) European patient voice in gout survey – subjective satisfaction in gout patients versus objective suboptimal gout care. ARD 78(S2):153–154
De Meulemeester M, Mateus E, Wieberneit-Tolman H et al (2020) Understanding the patient voice in gout: a quantitative study conducted in Europe. BJGP open. https://doi.org/10.3399/bjgpopen20X101003
Richette P, Clerson P, Perissin L, Flipo RM, Bardin T (2015) Revisiting comorbidities in a gout: a cluster analysis. ARD 74:142–147
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. ARD 76:29–42. https://doi.org/10.1136/annrheumdis-2-16-209707
Bardin T, Keenen RT, Khanna PP et al (2017) Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). ARD 76:811–820. https://doi.org/10.1136/annrheumdis-2016-209213
Saag KG, Fitz-Patrick D, Kopicko J et al (2016) Lesinurad combined with allopurinol: randomized, double-blind, placebo-controlled study in gout subjects with inadequate response to Standard of Care Allopurinol. Arthritis & Rheumatol. https://doi.org/10.1002/art.39840
Dalbeth N, Jones G, Terkeltaub R, Khanna D, Fung M, Baumgartner S, Perez-Ruiz F (2019) Efficacy and safety dering extended treatmentof lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. ART 21:8. https://doi.org/10.1186/s13075-018-1788-4
Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, Lioté F, Naden RP, Nuki G, Ogdie A, Perez-Ruiz F, Saag K, Singh JA, Sundy JS, Tausche AK, Vaquez-Mellado J, Yarows SA, Taylor WJ (2015) 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. ARD 74:1789–1798
Richette P, Doherty M, Pascual E et al (2019) 2018 updated EULAR evidence-based recommendations for the diagnosis of gout. ARD. https://doi.org/10.1136/annrheumdis-2019-215315
Doherty M, Jenkins W, Richardson H et al (2018) Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 392:1403–1412
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jansen, T.L., Janssen, M. Lessons and pitfalls from the 2020 Gout Clinical Practice Guideline presented in Atlanta at the ACR 2019. Clin Rheumatol 39, 2011–2016 (2020). https://doi.org/10.1007/s10067-020-05070-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-020-05070-y